Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note issued on Tuesday. The firm set a “sell” rating on the stock.

A number of other equities analysts also recently weighed in on the stock. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright reiterated a “neutral” rating and issued a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Price Performance

NASDAQ SYRS opened at $0.17 on Tuesday. The company has a market cap of $4.48 million, a P/E ratio of -0.06 and a beta of 1.30. Syros Pharmaceuticals has a 12 month low of $0.16 and a 12 month high of $7.96. The company has a 50-day moving average of $0.20 and a 200-day moving average of $1.13.

Institutional Trading of Syros Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Exome Asset Management LLC boosted its position in shares of Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after buying an additional 139,400 shares during the period. Two Sigma Securities LLC acquired a new position in Syros Pharmaceuticals during the 4th quarter worth approximately $25,000. Finally, GSA Capital Partners LLP acquired a new position in Syros Pharmaceuticals during the 3rd quarter worth approximately $34,000. 91.47% of the stock is owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.